Dulanermin
- Generic Name
- Dulanermin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 867153-61-5
- Unique Ingredient Identifier
- L65E7T81M5
- Background
Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00873756
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00671372
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00400764
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath